Jeito Capital leads $67.5 million (€64.4 million[1]) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease
07 janv. 2025 07h46 HE
|
Jeito Capital
Jeito Capital leads $67.5 million (€64.4 million1) Series B financing in XyloCor Therapeutics to develop Novel Gene Therapy in Cardiovascular Disease Proceeds of financing will support two...
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
07 janv. 2025 07h09 HE
|
Jeito Capital
Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ...
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
12 nov. 2024 07h10 HE
|
Jeito Capital
Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development ofAnti-Claudin-1 (CLDN1) ADCs in solid tumors ...
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
16 juil. 2024 05h10 HE
|
Jeito Capital
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for...
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion
29 mai 2024 07h02 HE
|
Jeito Capital
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects the significant clinical progress...
Jeito Capital co-leads EUR 65 million (USD 71 M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases
07 sept. 2023 03h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 65 million (USD 711M) financing in Corteria Pharmaceuticals, a French biopharmaceutical company developing novel treatments for cardiovascular diseases Jeito Capital...
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis
13 avr. 2023 01h15 HE
|
Jeito Capital
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in...
Jeito Capital dirige un financement de série C de 96 millions d’euros (105 millions de dollars) dans Alentis Therapeutics pour développer les traitements innovants ciblant la Claudin-1 dans les maladies fibrotiques et certains cancers
13 avr. 2023 01h15 HE
|
Jeito Capital
Jeito Capital dirige un financement de série C de 96 millions d’euros (105 millions de dollars) dans Alentis Therapeutics pour développer...
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
07 mars 2023 04h00 HE
|
Jeito Capital
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
07 mars 2023 04h00 HE
|
Jeito Capital
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...